The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Two leaders in science combine complementary best-in-class technologies for biologics manufacturing customers
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Filing marks first protein-based vaccine submitted to MHRA for authorization
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
Subscribe To Our Newsletter & Stay Updated
